Assessment of Extractables/Leachables Data in ANDA Submissions

FDA discusses common review issues encountered in ANDA applications on extractables/leachables studies, the kind of information FDA is looking for and how the FDA evaluates extractables/leachables data in ANDA applications.
Presenters:
Patricia Onyimba, MS
Branch Chief
Division of Liquid-Base Products I, OPQ | CDER
Kshitij (Kris) Patkar, PhD
Senior Pharmaceutical Quality Assessor
Office Pharmaceutical Manufacturing Assessment, OPQ | CDER
Learn more at: www.fda.gov/drugs/news-events...
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
 
Upcoming Training - www.fda.gov/cdersbia
SBIA Listserv - public.govdelivery.com/accoun...
SBIA 2021 Playlist - • 2021 CDER Small Busine...
SBIA LinkedIn: / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cdersbialearn
Twitter - / fda_drug_info
Email - [e-mail]  
Phone - [phone] I [phone]